Free tool
FAERS Monitor: Verzenio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208855 or its brand name (Verzenio, Abemaciclib). Reports on generic versions are filed under their own applications.
Reports
21,145
Serious
10,932
52% of reports
Hospitalization
4,417
Death reported
1,481
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea6,577
- fatigue2,834
- nausea2,345
- vomiting1,196
- malignant neoplasm progression1,148
- decreased appetite1,021
- asthenia941
- death811
- constipation767
- white blood cell count decreased761
- drug ineffective752
- abdominal pain upper735
- anaemia729
- neutropenia687
- off label use664
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 25 |
| 2018 | 850 |
| 2019 | 1,657 |
| 2020 | 1,648 |
| 2021 | 1,496 |
| 2022 | 2,192 |
| 2023 | 2,788 |
| 2024 | 3,399 |
| 2025 | 3,735 |
| 2026 | 3,345 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,014 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 1,148 | 11.3 | 10.6 | 10,660 |
| diarrhoeaSignal | 6,577 | 10.2 | 10.0 | 55,914 |
| white blood cell count decreasedSignal | 761 | 7.0 | 6.6 | 3,919 |
| neutropeniaSignal | 687 | 5.0 | 4.7 | 2,228 |
| decreased appetiteSignal | 1,021 | 4.4 | 4.1 | 2,685 |
| anaemiaSignal | 729 | 3.8 | 3.5 | 1,518 |
| fatigueSignal | 2,834 | 3.6 | 3.5 | 5,586 |
| abdominal pain upperSignal | 735 | 3.6 | 3.3 | 1,359 |
| constipationSignal | 767 | 3.5 | 3.3 | 1,382 |
| nauseaSignal | 2,345 | 3.0 | 2.8 | 3,136 |
| vomitingSignal | 1,196 | 2.5 | 2.4 | 1,132 |
| astheniaSignal | 941 | 2.5 | 2.3 | 853 |
| death | 811 | 0.9 | 0.9 | 4 |
| off label use | 664 | 0.8 | 0.7 | 55 |
| drug ineffective | 752 | 0.6 | 0.5 | 264 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.